# Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

> **NCT00079027** · PHASE3 · UNKNOWN · sponsor: **University Hospital Birmingham** · enrollment: 280 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **PROCEDURE:** hepatic artery embolization

## Key facts

- **NCT ID:** NCT00079027
- **Lead sponsor:** University Hospital Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079027, "Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00079027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*